prorso Guide Library Articles Features Enterprise
For teams
Sign inCreate account

Topic: evidence-strategy

Open in the app

How a research-based pharmaceutical manufacturer should fund the late-stage programme for its lead metabolic candidate

A large research-based pharmaceutical manufacturer decides how to pay for the pivotal clinical programme of its lead candidate in a highly prevalent chronic metabolic indication, at a point when several of its largest products are approaching the end of exclusivity. The log compares full internal funding, co-funding by a financial partner against success-based payments, sale of a participation in future product sales, a co-development and commercialisation agreement with another manufacturer, and a reduced programme funded internally. Options are compared on own development spend, lifetime economics retained, control of development and pricing, exposure if the programme fails, encumbrance on product assets, breadth of the evidence package and time until funding is in place. Readers can see how a financing choice is also a control and evidence-strategy choice, and how contingent, success-linked obligations are weighed against permanent claims on a product.

research and development funding, risk transfer, control and governance rights, evidence strategy, portfolio capacity

Read the whole template